VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Evoke Pharma, Inc. (EVOK) Total Return Calculator with Dividends Reinvested

Evoke Pharma, Inc.

Popular:

The total return for Evoke Pharma, Inc. (EVOK) stock is +253.70% over the past 12 months. The 5-year total return is -95.17%, meaning $10,000 invested in EVOK stock 5 years ago would be worth $483 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in EVOK 1 year ago, it would be worth $34,056 today — you'd have gained $24,056.

With Dividends Reinvested$34,056+240.56%

Price Only (No DRIP)$34,056+240.56%

Period2025-05-08 → 2025-12-17

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in EVOK

1Y$35,370+$25,370 (+253.7%)253.7% CAGR

3Y$4,117-$5,883 (-58.8%)-25.6% CAGR

5Y$483-$9,517 (-95.2%)-45.4% CAGR

10Y$153-$9,847 (-98.5%)-34.2% CAGR

15Y$65-$9,935 (-99.3%)-28.5% CAGR

20Y$65-$9,935 (-99.3%)-22.3% CAGR

30Y$65-$9,935 (-99.3%)-15.5% CAGR

Evoke Pharma, Inc. did not pay dividends during this period. Total return = price return.

Loading EVOK total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
1Y	+253.70%	253.70%	+253.70%	—	$35,370
3Y	-58.83%	-25.61%	-58.83%	—	$4,117
5Y	-95.17%	-45.44%	-95.17%	—	$483
10Y	-98.47%	-34.16%	-98.47%	—	$153
15Y	-99.35%	-28.52%	-99.35%	—	$65
20Y	-99.35%	-22.26%	-99.35%	—	$65
30Y	-99.35%	-15.45%	-99.35%	—	$65

Risk & Highlights

Best Year+146.09%2025

Worst Year-79.63%2021

Max Drawdown-48.07%2025-07-09 → 2025-07-31 · Recovered 2025-11-04

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2025	+146.09%	+146.09%	—	+16.64%	+129.4pp
2024	-64.24%	-64.24%	—	+24.00%	-88.2pp
2023	-61.11%	-61.11%	—	+24.81%	-85.9pp
2022	-62.32%	-62.32%	—	-19.95%	-42.4pp
2021	-79.63%	-79.63%	—	+28.79%	-108.4pp

EVOK outperformed the S&P 500 by 223.33pp over the past year (+253.70% vs +30.37%).

Loading summary...

EVOK Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
EVOKEvoke Pharma, Inc.	$19M	—	—	+253.7%	—	-58.8%	-95.2%	-98.5%
PRPOPrecipio, Inc.	$53M	+8.8%	+27.6%	+367.7%	—	+153.3%	-60.4%	-98.9%
AYTUAytu BioPharma, Inc.	$16M	-3.9%	-10.8%	+104.1%	—	+40.3%	-97.8%	-100.0%
TLSATiziana Life Sciences Ltd	$192M	+19.8%	-5.6%	-3.8%	—	+88.7%	-36.6%	-63.8%
MBRXMoleculin Biotech, Inc.	$29M	+3.3%	-31.2%	+149.2%	—	-79.2%	-95.0%	-99.7%
ANIPANI Pharmaceuticals, Inc.	$1.8B	+5.6%	+7.0%	+18.5%	—	+97.1%	+117.4%	+84.7%
HROWHarrow Health, Inc.	$1.5B	+10.2%	-21.8%	+58.8%	—	+43.0%	+378.0%	+914.3%
PRAXPraxis Precision Medicines, Inc.	$9.6B	+8.7%	+16.4%	+775.0%	—	+1976.5%	-20.8%	-20.1%
LPTXLeap Therapeutics, Inc.	$65M	—	-31.9%	+125.3%	—	-80.3%	-95.2%	-99.0%
NTRBNutriband Inc.	$46M	-5.3%	-14.4%	-34.4%	—	+10.8%	-34.0%	-34.0%
PAHCPhibro Animal Health Corporation	$1.7B	-22.5%	+16.0%	+125.1%	+2.5pp	+210.4%	+66.0%	+128.6%

Compare:EVOK vs PRPO EVOK vs AYTU EVOK vs TLSA EVOK vs PRPO vs AYTU

About EVOK Dividend Returns

Evoke Pharma, Inc. (EVOK) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of EVOK over the past year?

Evoke Pharma, Inc. (EVOK) delivered a return of 253.70% over the past year. Since EVOK does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in EVOK be worth today?

A $10,000 investment in Evoke Pharma, Inc. one year ago would be worth $35,370 today, representing a gain of $25,370.

Q3Does EVOK pay dividends?

Evoke Pharma, Inc. (EVOK) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For EVOK, the total return equals the price-only return.

Q4Did EVOK beat the S&P 500?

Yes, Evoke Pharma, Inc. (EVOK) outperformed the S&P 500 by 223.33 percentage points over the past year. EVOK delivered a total return of 253.70%, compared to the S&P 500's 30.37%. This 223.33pp alpha means investors in EVOK earned more than a passive S&P 500 index fund.

Q5What is EVOK's worst drawdown?

Evoke Pharma, Inc. (EVOK) experienced a maximum drawdown of -48.07% over the past year, declining from its peak on 2025-07-09 to its trough on 2025-07-31. The stock recovered to its prior peak by 2025-11-04. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is EVOK's long-term total return over 10, 20, or 30 years?

Here are Evoke Pharma, Inc. (EVOK)'s long-term returns with dividends reinvested. Over 10 years, the total return is -98.5% (-34.2% CAGR) — $10,000 would have grown to $153. Over 20 years: -99.3% total return (-22.3% CAGR) — $10,000 → $65. Over 30 years: -99.3% total return (-15.5% CAGR) — $10,000 → $65. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was EVOK's best and worst year?

Evoke Pharma, Inc.'s best calendar year was 2025 with a total return of 146.1%. Its worst year was 2021 with a total return of -79.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 225.7 percentage points.